Literature DB >> 2208973

Yellow fever haemagglutination-inhibiting, neutralising and IgM antibodies in vaccinated and unvaccinated residents of Ibadan, Nigeria.

S A Omilabu1, J O Adejumo, O D Olaleye, A H Fagbami, S S Baba.   

Abstract

A survey for yellow fever virus haemagglutination inhibiting (HI) and neutralising (N) and IgM antibodies was carried out in unvaccinated people in Ibadan and in those immunised with the yellow fever 17-D vaccine. A total of 207 people were tested for HI antibody to yellow fever and two other flaviviruses namely: Wesselsbron and Uganda S. viruses. Prevalence of HI antibody to each flavivirus antigen was as follows: Yellow fever 26%, Wesselsbron 18% and Uganda S 33%. Of the 207 people, 37 (18%) had yellow fever N antibody. There was a higher prevalence of N antibody to yellow fever virus in adults than children. Twenty-one people vaccinated with 17-D yellow fever vaccine donated post-vaccination sera; 10 (48%) had no prevaccination HI antibody, 7 (33%) had HI antibody to one flavivirus and 4 (19%) to two or more flaviviruses. Ninety percent of seronegative people and all those with prevaccination flavivirus antibodies developed HI or N antibody, following vaccination. A total of 58 unvaccinated people were tested for yellow fever IgM antibody by an enzyme linked immunosorbent assay, 2 (3%) were positive; suggesting that active yellow fever transmission was in progress at the time of survey.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2208973     DOI: 10.1016/0147-9571(90)90521-t

Source DB:  PubMed          Journal:  Comp Immunol Microbiol Infect Dis        ISSN: 0147-9571            Impact factor:   2.268


  6 in total

Review 1.  Efficacy and duration of immunity after yellow fever vaccination: systematic review on the need for a booster every 10 years.

Authors:  Eduardo Gotuzzo; Sergio Yactayo; Erika Córdova
Journal:  Am J Trop Med Hyg       Date:  2013-09       Impact factor: 2.345

2.  The effect of climate change on yellow fever disease burden in Africa.

Authors:  Katy Am Gaythorpe; Arran Hamlet; Laurence Cibrelus; Tini Garske; Neil M Ferguson
Journal:  Elife       Date:  2020-07-28       Impact factor: 8.140

3.  The global burden of yellow fever.

Authors:  Katy Am Gaythorpe; Arran Hamlet; Kévin Jean; Daniel Garkauskas Ramos; Laurence Cibrelus; Tini Garske; Neil Ferguson
Journal:  Elife       Date:  2021-03-16       Impact factor: 8.140

4.  Lives saved with vaccination for 10 pathogens across 112 countries in a pre-COVID-19 world.

Authors:  Jaspreet Toor; Susy Echeverria-Londono; Xiang Li; Kaja Abbas; Emily D Carter; Hannah E Clapham; Andrew Clark; Margaret J de Villiers; Kirsten Eilertson; Matthew Ferrari; Ivane Gamkrelidze; Timothy B Hallett; Wes R Hinsley; Daniel Hogan; John H Huber; Michael L Jackson; Kevin Jean; Mark Jit; Andromachi Karachaliou; Petra Klepac; Alicia Kraay; Justin Lessler; Xi Li; Benjamin A Lopman; Tewodaj Mengistu; C Jessica E Metcalf; Sean M Moore; Shevanthi Nayagam; Timos Papadopoulos; T Alex Perkins; Allison Portnoy; Homie Razavi; Devin Razavi-Shearer; Stephen Resch; Colin Sanderson; Steven Sweet; Yvonne Tam; Hira Tanvir; Quan Tran Minh; Caroline L Trotter; Shaun A Truelove; Emilia Vynnycky; Neff Walker; Amy Winter; Kim Woodruff; Neil M Ferguson; Katy Am Gaythorpe
Journal:  Elife       Date:  2021-07-13       Impact factor: 8.140

5.  Yellow Fever in Africa: estimating the burden of disease and impact of mass vaccination from outbreak and serological data.

Authors:  Tini Garske; Maria D Van Kerkhove; Sergio Yactayo; Olivier Ronveaux; Rosamund F Lewis; J Erin Staples; William Perea; Neil M Ferguson
Journal:  PLoS Med       Date:  2014-05-06       Impact factor: 11.069

6.  Quantifying model evidence for yellow fever transmission routes in Africa.

Authors:  Katy A M Gaythorpe; Kévin Jean; Laurence Cibrelus; Tini Garske
Journal:  PLoS Comput Biol       Date:  2019-09-23       Impact factor: 4.475

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.